Jeffrey Cummings – författare

Cognitive Enhancement in CNS Disorders and Beyond compiles a series of educational and thought-provoking chapters from the world's leading cognitive and clinical scientists to describe the latest research on cognitive impairments in a host of pathological conditions that affect CNS functioning, what treatments are available for these impairments, and how new treatments are being tested. This volume will benefit any investigators in cognitive science and clinical research, but is also accessible to non-experts. It advances the field toward the availability of cognitive enhancing drugs and devices that will benefit those who need them most and others who may feel that these techniques can help them to thrive. There has never been a time that we knew more about cognition and never a time when cognition was more important to the functioning of human beings than right now. Psychological science and cognitive neuroscience have become the most popular endeavor of students world wide, is the focus of attention of our greatest scientific accomplishments and the emphasis of many publications in the mainstream media. Since humans depend on cognitive abilities for survival, quality of life, and productivity, improving it has never been more important. Those with impairments in key aspects of cognition suffer dearly, as they are unable to obtain and retain information, unable to make sound decisions based upon the information at hand, and unable to plan future activities. The availability of pharmacological and behavioral interventions that can improve cognitive abilities and provide impaired individuals with the social, occupational and functional quality of life that the rest of us enjoy has potential far-reaching implications. Such interventions can also benefit those who want to boost current cognitive abilities to higher levels, perhaps as a means to hone skills in providing products for others or to gain an edge on competition. There has never been a book devoted solely to describing the latest cognitive science and neuroscience on the methods for enhancing cognition in healthy and unhealthy humans. Cognitive Enhancement in CNS Disorders and Beyond accomplishes exactly that in a straightforward and accessible manner.

Translating laboratory discoveries into successful therapeutics can be difficult. Clinical Trials in Neurology aims to improve the efficiency of clinical trials and the development of interventions in order to enhance the development of new treatments for neurologic diseases. It introduces the reader to the key concepts underpinning trials in the neurosciences. This volume tackles the challenges of developing therapies for neurologic disorders from measurement of agents in the nervous system to the progression of clinical signs and symptoms through illustrating specific study designs and their applications to different therapeutic areas. Clinical Trials in Neurology covers key issues in Phase I, II and III clinical trials, as well as post-marketing safety surveillance. Topics addressed include regulatory and implementation issues, outcome measures and common problems in drug development. Written by a multidisciplinary team, this comprehensive guide is essential reading for neurologists, psychiatrists, neurosurgeons, neuroscientists, statisticians and clinical researchers in the pharmaceutical industry.

Psychiatric and cognitive changes are common in patients with Parkinson's disease and have key clinical consequences but, despite this, these symptoms are often under-diagnosed and under-treated, leading to increased morbidity and costs. With chapters focused on the major neuropsychiatric features, Neuropsychiatric and Cognitive Changes in Parkinson's Disease and Related Movement Disorders rectifies this deficit. Written by experts in the field, with a consistent focus on relevant clinical knowledge, it provides a comprehensive overview including all the major behavioral changes associated with movement disorders. The book provides broad, in-depth, accurate and up-to-date scientific information as well as crucial understanding and practical tools to help patients. The book is essential reading for clinicians working in neurology, psychiatry and geriatric medicine.

Psychiatric and cognitive changes are common in patients with Parkinson''s disease and have key clinical consequences but, despite this, these symptoms are often under-diagnosed and under-treated, leading to increased morbidity and costs. With chapters focused on the major neuropsychiatric features, Neuropsychiatric and Cognitive Changes in Parkinson''s Disease and Related Movement Disorders rectifies this deficit. Written by experts in the field, with a consistent focus on relevant clinical knowledge, it provides a comprehensive overview including all the major behavioral changes associated with movement disorders. The book provides broad, in-depth, accurate and up-to-date scientific information as well as crucial understanding and practical tools to help patients. The book is essential reading for clinicians working in neurology, psychiatry and geriatric medicine.

Psychiatric and cognitive changes are common in patients with Parkinson''s disease and have key clinical consequences but, despite this, these symptoms are often under-diagnosed and under-treated, leading to increased morbidity and costs. With chapters focused on the major neuropsychiatric features, Neuropsychiatric and Cognitive Changes in Parkinson''s Disease and Related Movement Disorders rectifies this deficit. Written by experts in the field, with a consistent focus on relevant clinical knowledge, it provides a comprehensive overview including all the major behavioral changes associated with movement disorders. The book provides broad, in-depth, accurate and up-to-date scientific information as well as crucial understanding and practical tools to help patients. The book is essential reading for clinicians working in neurology, psychiatry and geriatric medicine.

Alzheimer's Disease (AD) is a growing global public health challenge. The development of new therapies is urgently needed, and a complex ecosystem of organizations has grown to facilitate AD drug discovery and development. Masterfully collating information on the drug development ecosystem, this book emphasizes the contributions of each aspect in the pipeline with a uniform approach to chapters, enabling readers to access relevant information quickly. Topics covered include the use of non-clinical laboratory studies, biomarker development, artificial intelligence, design and management of clinical trials, and funding and financing models. Also discussed is the critical role of advocacy fundraising for drug development. With the approval of aducanumab, the function of the ecosystem has become apparent. This is a definitive overview of how the ecosystem works in transferring an AD drug from its discovery in the laboratory through clinical trial testing to regulatory review and eventual marketing.

Alzheimer''s Disease (AD) is a growing global public health challenge. The development of new therapies is urgently needed, and a complex ecosystem of organizations has grown to facilitate AD drug discovery and development. Masterfully collating information on the drug development ecosystem, this book emphasizes the contributions of each aspect in the pipeline with a uniform approach to chapters, enabling readers to access relevant information quickly. Topics covered include the use of non-clinical laboratory studies, biomarker development, artificial intelligence, design and management of clinical trials, and funding and financing models. Also discussed is the critical role of advocacy fundraising for drug development. With the approval of aducanumab, the function of the ecosystem has become apparent. This is a definitive overview of how the ecosystem works in transferring an AD drug from its discovery in the laboratory through clinical trial testing to regulatory review and eventual marketing.

Alzheimer''s Disease (AD) is a growing global public health challenge. The development of new therapies is urgently needed, and a complex ecosystem of organizations has grown to facilitate AD drug discovery and development. Masterfully collating information on the drug development ecosystem, this book emphasizes the contributions of each aspect in the pipeline with a uniform approach to chapters, enabling readers to access relevant information quickly. Topics covered include the use of non-clinical laboratory studies, biomarker development, artificial intelligence, design and management of clinical trials, and funding and financing models. Also discussed is the critical role of advocacy fundraising for drug development. With the approval of aducanumab, the function of the ecosystem has become apparent. This is a definitive overview of how the ecosystem works in transferring an AD drug from its discovery in the laboratory through clinical trial testing to regulatory review and eventual marketing.

Jewish Mystical tradition - the Kabbalah. The vibrancy and spiritual uplift at the heartbeat of Judaism - the Torah and Mitzvot.

This manual takes a multidisciplinary approach to neurological disorders in the elderly. Comprehensive and practical, it includes the most recent diagnostic criteria and immediately accessible visual care paths including the latest pharmacologic and non-pharmacologic interventions.Covering a range of modalities, from the importance and impact of each disease to diagnostic criteria, genetics, laboratory and imaging findings, treatment and care paths, this book focuses on neurological conditions that occur commonly in older persons or which have a striking effect on their lives. The common types of dementias, Parkinson’s disease and related disorders, rapidly progressive diseases,  seizure disorders and multiple sclerosis are covered. Issues commonly affecting this population, such as neurobehavioral symptoms and caregiver issues, are discussed. Neuro-Geriatrics: A Clinical Manual is aimed at any physician who treats the elderly with neurological disorders: neurologists, geriatricians and geriatric psychiatrists, both specialists and general practitioners.

This manual takes a multidisciplinary approach to neurological disorders in the elderly. Comprehensive and practical, it includes the most recent diagnostic criteria and immediately accessible visual care paths including the latest pharmacologic and non-pharmacologic interventions.

Covering a range of modalities, from the importance and impact of each disease to diagnostic criteria, genetics, laboratory and imaging findings, treatment and care paths, this book focuses on neurological conditions that occur commonly in older persons or which have a striking effect on their lives. The common types of dementias, Parkinson’s disease and related disorders, rapidly progressive diseases,  seizure disorders and multiple sclerosis are covered. Issues commonly affecting this population, such as neurobehavioral symptoms and caregiver issues, are discussed.

Neuro-Geriatrics: A Clinical Manual is aimed at any physician who treats the elderly with neurological disorders: neurologists, geriatricians and geriatric psychiatrists, both specialists and general practitioners.